Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Ocana

Showing results (41-50 of 98) with videos related to

Pageof 10
Sort By:
Frontiers in Immunology|August 15, 2024
Overcoming limitations for antibody-based therapies targeting γδ T (Vg9Vd2) cellsLucía Paniagua-Herranz, Cristina Díaz-Tejeiro, Adrián Sanvicente, et al.
Cancer Treatment Reviews|July 23, 2017
Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancerHadar Goldvaser, Domen Ribnikar, Rouhi Fazelzad, et al.
BMC Cancer|May 1, 2014
Phospho-kinase profile of triple negative breast cancer and androgen receptor signalingMaría D Cuenca-López, Juan C Montero, Jorge C Morales, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2014
Raising concern about the American Society of Clinical Oncology conflict of interest policy amendmentFrancisco E Vera-Badillo, Alberto Ocana, Arnoud J Templeton, et al.
Molecular Diagnosis & Therapy|February 2, 2022
Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-AnalysisRamy R Saleh, Jordan L Scott, Nicholas Meti, et al.
Scientific Reports|May 26, 2021
Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decadeDomen Ribnikar, Hadar Goldvaser, Zachary W Veitch, et al.
The Lancet. Oncology|June 15, 2016
Under-reporting of harm in clinical trialsBostjan Seruga, Arnoud J Templeton, Francisco Emilio Vera Badillo, et al.
Geroscience|June 19, 2025
NRF2 pathway activation predicts poor prognosis in lung cancer: a cautionary note on antioxidant interventionsZoltan Ungvari, Otília Menyhart, Andrea Lehoczki, et al.
Plos One|March 4, 2014
Extended adjuvant tamoxifen for early breast cancer: a meta-analysisMustafa Al-Mubarak, Ariadna Tibau, Arnoud J Templeton, et al.
Cancer Treatment Reviews|April 25, 2017
Efficacy, safety, tolerability and price of newly approved drugs in solid tumorsTristan A Barnes, Eitan Amir, Arnoud J Templeton, et al.
Pageof 10

Showing results (41-50 of 98) with videos related to

Sort By:
Pageof 10
Frontiers in Immunology|August 15, 2024
Overcoming limitations for antibody-based therapies targeting γδ T (Vg9Vd2) cellsLucía Paniagua-Herranz, Cristina Díaz-Tejeiro, Adrián Sanvicente, et al.
Cancer Treatment Reviews|July 23, 2017
Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancerHadar Goldvaser, Domen Ribnikar, Rouhi Fazelzad, et al.
BMC Cancer|May 1, 2014
Phospho-kinase profile of triple negative breast cancer and androgen receptor signalingMaría D Cuenca-López, Juan C Montero, Jorge C Morales, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2014
Raising concern about the American Society of Clinical Oncology conflict of interest policy amendmentFrancisco E Vera-Badillo, Alberto Ocana, Arnoud J Templeton, et al.
Molecular Diagnosis & Therapy|February 2, 2022
Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-AnalysisRamy R Saleh, Jordan L Scott, Nicholas Meti, et al.
Scientific Reports|May 26, 2021
Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decadeDomen Ribnikar, Hadar Goldvaser, Zachary W Veitch, et al.
The Lancet. Oncology|June 15, 2016
Under-reporting of harm in clinical trialsBostjan Seruga, Arnoud J Templeton, Francisco Emilio Vera Badillo, et al.
Geroscience|June 19, 2025
NRF2 pathway activation predicts poor prognosis in lung cancer: a cautionary note on antioxidant interventionsZoltan Ungvari, Otília Menyhart, Andrea Lehoczki, et al.
Plos One|March 4, 2014
Extended adjuvant tamoxifen for early breast cancer: a meta-analysisMustafa Al-Mubarak, Ariadna Tibau, Arnoud J Templeton, et al.
Cancer Treatment Reviews|April 25, 2017
Efficacy, safety, tolerability and price of newly approved drugs in solid tumorsTristan A Barnes, Eitan Amir, Arnoud J Templeton, et al.
Pageof 10